<DOC>
	<DOCNO>NCT00593255</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare efficacy postprandial plasma glucose two treatment regimen Chinese subject .</brief_summary>
	<brief_title>Efficacy Safety Insulin Aspart Subjects With Type 1 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 2 diabetes least 4 week Treatment oral antidiabetic drug ( OADs ) and/or insulin least 4 week HbA1c : 7.513.5 % Body Mass Index ( BMI ) : 1835 kg/m2 Treatment either soluble human insulin insulin NPH three time daily within 3 month trial participation History drug abuse alcohol dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>